Subsequently, the efficacy of the dual combination treatment of alectinib or lorlatinib with two pan-HER inhibitors dacomitinib or neratinib was confirmed by a suppression of cell growth using two ALK + NSCLC lung cancer cell lines and reduction in subcutaneous ALK1510-c4 cell xenograft tumors in mice. The gene discussed is ALK; the disease is lung cancer.